Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028 - Visiongain Report

LONDON, July 24, 2018 /PRNewswire/ --

Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures- all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global ophthalmic drugs market revenue forecasts from 2018-2028

• Global ophthalmic drugs market revenue forecasts from 2018-2028, by submarket:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:
• Alphagan
• Avastin
• Azopt
• Eylea
• Lucentis
• Lumigan & Ganfort
• Other Ophthalmic Drugs
• Restasis
• Vigamix
• Xalatan/Xalacom

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Acucela
• Akorn
• Alimera Sciences
• Allergan
• Amakem
• Bayer
• Chengdu Kanghong
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Biosciences
• MacuCLEAR
• Neurotech
• Novartis
• Omeros
• Ophthotech
• Otsuka Pharmaceutical
• Pfizer
• pSivida Corp.
• Regeneron
• Roche
• Santen
• Senju
• Shire
• ThromboGenics
• Valeant

• Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant

• Our report provides these Qualitative Analysis:
• Drivers and Restraints of the Global Ophthalmic Drugs market
• SWOT Analysis of selected leading companies
• Porter's Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain's study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/pharma-leader-series-top-25-ophthalmic-drug-manufacturers-2018-2028/

Abbott Laboratories (Abbott)
Abbvie
Actavis
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allergan
Allegro Ophthalmics
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
BioDiem
Bicycle Therapeutics
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
Inception Sciences, Inc.
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Versant Ventures
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com